Market Watch: Strategic Shift to U.S. 503A Compounding\n\nIn a notable market development, The Precision Peptide Company Inc. has officially signed an agreement with a U.S.-based 503A sterile compounding pharmacy, ensuring that all of its peptide prescriptions will now be compounded domestically. According to the company's CEO, Pratap Sandhu, the move is designed to strengthen their U.S. supply chain and regulatory footprint The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States. This development comes as the industry awaits formal rulemaking from the FDA following the Pharmacy Compounding Advisory Committee's (PCAC) July 2026 review of bulk drug substances like BPC-157.\n\n### Regulatory & Enforcement: Fallout from Telehealth Compounding Gaps\n\nMeanwhile, industry analysts are dissecting the operational implications of recent FDA enforcement actions, particularly the warning issued to Medvi. Reports indicate that Medvi operated without a licensed pharmacy and utilized fake testimonials, exposing significant compliance gaps in the GLP-1 compounding space Medvi FDA Warning Exposes GLP-1 Compounding Gaps | Pharma Now. Quality assurance directors are being warned that the FDA is likely to accelerate its scrutiny of asynchronous telehealth prescribing, especially when it intersects with compounded product supply chains lacking proper sterility assurance or process validation records.\n\n### Compliance Takeaway\n\nFor research-peptide suppliers like RP Wellness, the market is clearly bifurcating. Companies are increasingly seeking safe harbor by partnering directly with heavily regulated, U.S.-based 503A facilities. As the FDA continues to target asynchronous prescribing and unverified supply chains, maintaining rigorous, documented compliance and transparent sourcing will be critical to surviving the current enforcement climate.